Opioid Use Disorder Comorbidity in Individuals With Schizophrenia-Spectrum Disorders: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 (4) ◽  
pp. 26-37
Author(s):  
Marlon Danilewitz ◽  
Anees Bahji
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Opioid Use Disorder ◽  
Schizophrenia Spectrum Disorders ◽  
Opioid Use ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression

2019 ◽  
Vol 49 (15) ◽  
pp. 2463-2474 ◽  
Author(s):  
Sarah E. Herniman ◽  
Kelly Allott ◽  
Lisa J. Phillips ◽  
Stephen J. Wood ◽  
Jacqueline Uren ◽  
...  
Keyword(s):  
Systematic Review ◽  
Depressive Disorder ◽  
Meta Analysis ◽  
First Episode ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Pooled Prevalence ◽  
Meta Regression ◽  
Spectrum Disorders ◽  
First Episode Schizophrenia

AbstractBackgroundDespite knowing for many decades that depressive psychopathology is common in first-episode schizophrenia spectrum disorders (FES), there is limited knowledge regarding the extent and nature of such psychopathology (degree of comorbidity, caseness, severity) and its demographic, clinical, functional and treatment correlates. This study aimed to determine the pooled prevalence of depressive disorder and caseness, and the pooled mean severity of depressive symptoms, as well as the demographic, illness, functional and treatment correlates of depressive psychopathology in FES.MethodsThis systematic review, meta-analysis and meta-regression was prospectively registered (CRD42018084856) and conducted in accordance with PRISMA and MOOSE guidelines.ResultsForty studies comprising 4041 participants were included. The pooled prevalence of depressive disorder and caseness was 26.0% (seven samples, N = 855, 95% CI 22.1–30.3) and 43.9% (11 samples, N = 1312, 95% CI 30.3–58.4), respectively. The pooled mean percentage of maximum depressive symptom severity was 25.1 (38 samples, N = 3180, 95% CI 21.49–28.68). Correlates of depressive psychopathology were also found.ConclusionsAt least one-quarter of individuals with FES will experience, and therefore require treatment for, a full-threshold depressive disorder. Nearly half will experience levels of depressive symptoms that are severe enough to warrant diagnostic investigation and therefore clinical intervention – regardless of whether they actually fulfil diagnostic criteria for a depressive disorder. Depressive psychopathology is prominent in FES, manifesting not only as superimposed comorbidity, but also as an inextricable symptom domain.

Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis

2011 ◽  
Vol 125 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Clarissa Trzesniak ◽  
Irismar R. Oliveira ◽  
Matthew J. Kempton ◽  
Amanda Galvão-de Almeida ◽  
Marcos H.N. Chagas ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Septum Pellucidum ◽  
Schizophrenia Spectrum Disorders ◽  
Cavum Septum Pellucidum ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals Autistic Symptoms in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 10 ◽  
Author(s):  
Franco De Crescenzo ◽  
Valentina Postorino ◽  
Martina Siracusano ◽  
Assia Riccioni ◽  
Marco Armando ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Autistic Symptoms ◽  
Spectrum Disorders

scholarly journals Can metacognitive interventions improve insight in schizophrenia spectrum disorders? A systematic review and meta-analysis

2020 ◽  
Vol 50 (14) ◽  
pp. 2289-2301
Author(s):  
Javier-David Lopez-Morinigo ◽  
Olesya Ajnakina ◽  
Adela Sánchez-Escribano Martínez ◽  
Paula-Jhoana Escobedo-Aedo ◽  
Verónica González Ruiz-Ruano ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Post Treatment ◽  
Medium Effect ◽  
Schizophrenia Spectrum Disorders ◽  
Metacognitive Training ◽  
Cognitive Insight ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

AbstractBackgroundPatients with schizophrenia spectrum disorders (SSD) tend to lack insight, which is linked to poor outcomes. The effect size of previous treatments on insight changes in SSD has been small. Metacognitive interventions may improve insight in SSD, although this remains unproved.MethodsWe carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine the effects of metacognitive interventions designed for SSD, namely Metacognitive Training (MCT) and Metacognitive Reflection and Insight Therapy (MERIT), on changes in cognitive and clinical insight at post-treatment and at follow-up.ResultsTwelve RCTs, including 10 MCT RCTs (n = 717 participants) and two MERIT trials (n = 90), were selected, totalling N = 807 participants. Regarding cognitive insight six RCTs (n = 443) highlighted a medium effect of MCT on self-reflectiveness at post-treatment, d = 0.46, p < 0.01, and at follow-up, d = 0.30, p < 0.01. There was a small effect of MCT on self-certainty at post-treatment, d = −0.23, p = 0.03, but not at follow-up. MCT was superior to controls on an overall Composite Index of cognitive insight at post-treatment, d = 1.11, p < 0.01, and at follow-up, d = 0.86, p = 0.03, although we found evidence of heterogeneity. Of five MCT trials on clinical insight (n = 244 participants), which could not be meta-analysed, four of them favoured MCT compared v. control. The two MERIT trials reported conflicting results.ConclusionsMetacognitive interventions, particularly Metacognitive Training, appear to improve insight in patients with SSD, especially cognitive insight shortly after treatment. Further long-term RCTs are needed to establish whether these metacognitive interventions-related insight changes are sustained over a longer time period and result in better outcomes.

Sign in / Sign up

Export Citation Format

Share Document